Zhao P, Liang L-L, Luo Y-B, Liang Q-K, Xiang B-D
Department of Head and Neck Surgery, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, People's Republic of China.
Pathology Department, The Second Nanning People's Hospital, Nanning, Guangxi, People's Republic of China.
ANZ J Surg. 2025 Jan-Feb;95(1-2):26-33. doi: 10.1111/ans.19210. Epub 2024 Oct 22.
In this study, we aimed to assess the effect of prophylactic central compartment neck dissection (pCCND) in conjunction with hemithyroidectomy (HT) for clinically low-risk node-negative (cN0) papillary thyroid carcinoma (PTC).
A thorough literature search was performed utilizing PubMed and EMBASE for articles published until October 2023. Subsequently, a meta-analysis was performed on studies involving patients with cN0 PTC, with postoperative locoregional recurrence (LRR) and survival data, treated with HT + pCCND or HT. The study was registered with PROSPERO (CRD42024560962).
We included seven studies in this meta-analysis, including 2132 patients who met the inclusion criteria: six retrospective cohort studies and one randomized controlled trial. The HT + pCCND group consisted of 1090 cases, and the HT group had 1042 cases. The LRR rates after HT with or without pCCND were similar (3.58% vs. 4.51%; odds ratio (OR) = 0.65; 95% confidence interval (CI) = 0.41-1.03). Five of the seven studies provided prognostic and survival data, particularly the log hazard ratio (log HR) of disease-free survival (DFS) between the two groups. There was also no significant difference in terms of DFS between the HT + pCCND and HT groups (OR = 0.67; 95% CI = 0.42-1.07).
There was no significant difference in LRR and DFS between the HT + pCCND and HT groups. pCCND did not demonstrate significant efficacy in improving oncological outcomes for low-risk patients with cN0 PTC. Therefore, for patients with low-risk cN0 PTC, thyroid surgeons should make reasonable and individualized decisions regarding the extent of surgical removal.
在本研究中,我们旨在评估预防性中央区颈淋巴结清扫术(pCCND)联合甲状腺半叶切除术(HT)对临床低风险、淋巴结阴性(cN0)的乳头状甲状腺癌(PTC)的疗效。
利用PubMed和EMBASE对截至2023年10月发表的文章进行了全面的文献检索。随后,对涉及接受HT + pCCND或HT治疗的cN0 PTC患者的研究进行了荟萃分析,这些研究包含术后局部区域复发(LRR)和生存数据。该研究已在PROSPERO注册(CRD42024560962)。
我们在这项荟萃分析中纳入了7项研究,包括2132例符合纳入标准的患者:6项回顾性队列研究和1项随机对照试验。HT + pCCND组有1090例,HT组有1042例。HT联合或不联合pCCND后的LRR率相似(3.58%对4.51%;优势比(OR)= 0.65;95%置信区间(CI)= 0.41 - 1.03)。7项研究中的5项提供了预后和生存数据,特别是两组之间无病生存(DFS)的对数风险比(log HR)。HT + pCCND组和HT组之间的DFS也没有显著差异(OR = 0.67;95% CI = 0.42 - 1.07)。
HT + pCCND组和HT组之间的LRR和DFS没有显著差异。pCCND在改善低风险cN0 PTC患者的肿瘤学结局方面未显示出显著疗效。因此,对于低风险cN0 PTC患者,甲状腺外科医生应就手术切除范围做出合理且个体化的决策。